ATC/DDD Classification - Temporary lists
ATC/DDD Classification - Final lists
The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology 29 October 2001. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2002. If no objections are received before this date, the new ATC codes and DDDs will be considered final and be included in the January 2003 issue of the ATC index.
| Aminolevulinic acid | L01XD04 |
| Apomorphine | G04BE07 |
| Bosentan | C02KX01 |
| Butenafine | D01AE23 |
| Calcipotriol, combinations | D05AX52 |
| Choriogonadotropin alfa | G03GA08 |
| Delapril and calcium channel blockers | C09BB12 |
| Dutasteride | G04CB02 |
| Eletriptan | N02CC06 |
| Famotidine, combinations | A02BA53 |
| Ferric sodium gluconate complex | B03AC07 |
| Fondaparinux | B01AX05 |
| Gepirone | N06AX19 |
| Lafutidine | A02BA08 |
| Meningococcus C, purified polysaccarides antigen conjugated | J07AH07 |
| Miglustat | A16AX06 |
| Pegfilgrastim | L03AA13 |
| Seratrodast | R03DX06 |
| Simvastatin, combination packages | C10AA51 |
| Sulphur hexafluoride | V08DA05 |
| Tadalafil | G04BE08 |
| Tenecteplase | B01AD11 |
| Teriparatide | H05AA02 |
| Voriconazole | J02AC03 |
| Xaliproden | N07XX03 |
| Other antihypertensives | C02KX |
| Previous | New | ATC code |
| Parathyroid hormones | Parathyroid hormones and analogues | H05A |
| Parathyroid hormones | Parathyroid hormones and analogues | H05AA |
| INN/common name | DDD |
Unit |
Adm.R |
ATC code |
| Agalsidase alfa | 1 |
mg |
P |
A16AB03 |
| Agalsidase beta | 5 |
mg |
P |
A16AB04 |
| Amisulpride | 0.1 |
g |
O |
N05AL05 |
| Amprenavir | 2.4 |
g |
O |
J05AE05 |
| Apomorphine* | 2 |
mg |
SL |
G04BE07 |
| Ascorbic acid | 0.25 |
g |
V |
G01AD03 |
| Baclofen | 0.55 |
mg |
P |
M03BX01 |
| Bisoxatin | 0.12 |
g |
O |
A06AB09 |
| Diosmectite | 9 |
g |
O |
A07BC05 |
| Eletriptan* | 40 |
mg |
O |
N02CC06 |
| Estradiol | 0.3 |
mg |
N |
G03CA03 |
| Lafutidine* | 20 |
mg |
O |
A02BA08 |
| Levosimendan | 11 |
mg |
P |
C01CX08 |
| Linezolid | 1.2 |
g |
O, P |
J01XX08 |
| Lopinavir | 8 |
g |
O |
J05AE06 |
| Lornoxicam | 12 |
mg |
P, R |
M01AC05 |
| Lutropin alfa | 75 |
U |
P |
G03GA07 |
| Naltrexone | 50 |
mg |
O |
N07BB04 |
| Nateglinide | 0.36 |
g |
O |
A10BX03 |
| Rasburicase | 14 |
mg |
P |
V03AF07 |
| Rupatadine | 10 |
mg |
O |
R06AX28 |
| Sibutramine | 10 |
mg |
O |
A08AA10 |
| Sirolimus | 6 |
mg |
O |
L04AA10 |
| Sodium selenite | 0.2 |
mg |
O, P |
A12CE02 |
| Terlipressin | 12 |
mg |
P |
H01BA04 |
| Unoprostone | 0.2 |
ml |
S01EX04 |
* Temporary ATC code
| INN/common name | Previsous DDD | Unit | Adm.R | New DDD | Unit | Adm.R | ATC code |
| Budesonide | 0.3 | mg | N | 0.2 | mg | N | R01AD05 |
The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology 4 - 6 June 2001. They came into force 15 September 2001.
| Acetyldigoxin, combinations | C01AA52 |
| Agalsidase alfa | A16AB03 |
| Agalsidase beta | A16AB04 |
| Amlexanox | A01AD07 |
| Anakinra | L04AA14 |
| Arsenic trioxide | L01XX27 |
| Ascorbic acid | G01AD03 |
| Ascorbic acid | S01XA15 |
| Bisoxatin | A06AB09 |
| BMP-2 | M05BC01 |
| BMP-7 | M05BC02 |
| Cilnidipine | C08CA14 |
| Crilanomer | D03AX09 |
| Darbepoetin alfa | B03XA02 |
| Denileukin diftitox | L01XX29 |
| Dienogest and estrogen | G03FA15 |
| Diflucortolone | D07XC04 |
| Dimethyl sulfoxide | G04BX13 |
| Drotrecogin alfa (activated) | B01AD10 |
| Esomeprazole, amoxicillin and clarithromycin | A02BD06 |
| Fomepizole | V03AB34 |
| Formoterol and other drugs for obstructive airway diseases | R03AK07 |
| Fulvestrant | L02BA03 |
| Gadobutrol | V08CA09 |
| Hemoglobin raffimer | B05AA09 |
| Imatinib | L01XX28 |
| Insulin glargine | A10AE04 |
| Levocetirizine | R06AE08 |
| Lutropin alfa | G03GA07 |
| Methyl aminolevulinate | L01XD03 |
| Monobenzone | D11AX13 |
| Multienzymes and acid preparations | A09AC02 |
| Omalizumab | R03DX05 |
| Phloroglucinol | A03AX12 |
| Rupatadine | R06AX28 |
| Sodium selenite | A12CE02 |
| Sodium tartrate | A06AD21 |
| Tacrolimus | D11AX14 |
| Talinolol | C07AB13 |
| Tegafur, combinations | L01BC53 |
| Thioacetazone, combinations | J04AM04 |
| Tiotropium bromide | R03BB04 |
| Trimegestone and estrogen | G03FB11 |
| Unoprostone | S01EX04 |
| Vaginal ring with progestogen and estrogen | G02BB01 |
| Zinc acetate | A16AX05 |
| Agents used in photodynamic therapy | L01XD |
| Bone morphogenetic proteins | M05BC |
| Previous ATC | New ATC | |
| Porfimer sodium | L01XX15 | L01XD01 |
| Verteporfin | L01XX26 | L01XD02 |
| Alginic acid | A02EA01 | A02BX13 |
| Silicones | A02DA01 | A03AX13 |
| Previous | New | ATC code |
| Antacids, drugs for treatment of peptic ulcer and flatulence | Drugs for acid related disorders | A02 |
| Drug for treatment of peptic ulcer | Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | A02B |
| Other drugs for treatment of peptic ulcer | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | A02BX |
| Other antacids, drugs for treatment of peptic ulcer and flatulence | Other drugs for acid related disorders | A02X |
| Antispasmodic and anticholinergic agents and propulsives | Drugs for functional gastrointestinal disorders | A03 |
| Synthetic antispasmodic and anticholinergic agents | Drugs for functional bowel disorders | A03A |
| Other synthetic anticholinergic agents | Other drugs for functional bowel disorders | A03AX |
| Drugs affecting mineralization Other drugs affecting mineralization |
Drugs affecting bone structure and mineralization Other drugs affecting bone structure and mineralization |
M05B M05BX |
| Anti-asthmatics | Drugs for obstructive airway diseases | R03 |
| Adrenergics and other anti-asthmatics | Adrenergics and other drugs for obstructive airway diseases | R03AK |
| Epinephrine and other anti-asthmatics | Epinephrine and other drugs for obstructive airway diseases | R03AK01 |
| Isoprenaline and other anti-asthmatics | Isoprenaline and other drugs for obstructive airway diseases | R03AK02 |
| Fenoterol and other anti-asthmatics | Fenoterol and other drugs for obstructive airway diseases | R03AK03 |
| Salbutamol and other anti-asthmatics | Salbutamol and other drugs for obstructive airway diseases | R03AK04 |
| Reproterol and other anti-asthmatics | Reproterol and other drugs for obstructive airway diseases | R03AK05 |
| Salmeterol and other anti-asthmatics | Salmeterol and other drugs for obstructive airway diseases | R03AK06 |
| Other anti-asthmatics, inhalants | Other drugs for obstructive airway diseases, inhalants | R03B |
| Other anti-asthmatics, inhalants | Other drugs for obstructive airway diseases, inhalants | R03BX |
| Adrenergics and other anti-asthmatics | Adrenergics and other drugs for obstructive airway diseases | R03CK |
| Other anti-asthmatics for systemic use | Other systemic drugs for obstructive airway diseases | R03D |
| Other anti-asthmatics for systemic use | Other systemic drugs for obstructive airway diseases | R03DX |
| INN/common name | DDD | Unit | Adm.R | ATC code |
| Almotriptan | 12.5 |
mg | O | N02CC05 |
| Buprenorphine | 8 |
mg | O | N07BC01 |
| Cilnidipine | 10 |
mg | O | C08CA14 |
| Darbepoetin alfa | 4.5 |
mcg | P | B03XA02 |
| Desloratadine | 5 |
mg | O | R06AX27 |
| Itraconazole | 0.2 |
g | P | J02AC02 |
| Levocetirizine | 5 |
mg | O | R06AE08 |
| Mifepristone | 0.6 |
g | O | G03XB01 |
| Mycofenolic acid | 2 |
g | P | L04AA06 |
| Nimesulide | 0.2 |
g | O | M01AX17 |
| Peginterferon alfa-2b | 7.5 |
mcg | P | L03AB10 |
| Propacetamol | 6 |
g | P | N02BE05 |
| Talinolol | 0.1 |
g | O | C07AB13 |
| Tobramycin | 0.3 |
g | Inhal. sol. | J01GB01 |
| Zinc acetate | 0.15 |
g | O | A16AX05 |
| INN/common name | Previsous DDD | Unit | Adm.R | New DDD | Unit | Adm.R | ATC code |
| Erythropoietin | 2 | TU | P | 1 | TU | P | B03XA01 |
| Risedronic acid | 30 | mg | O | 5 | mg | O | M05BA07 |
Consultations concerning revision of ATC groups or DDDs can be initiated by the Centre.
For further information about the procedure, deadlines etc. please contact the Centre.